 OCALA, Fla., Oct. 19, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced that it has submitted an Investigational New Drug application IND and an accompanying application for Fast Track status with the U.S. Food and Drug Administration FDA for a planned Phase 2 study of the companys drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. 